Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to be increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain.
Published Literature and the Steadily Growing IP Portfolio Validate the Underlying Importance
Bioavailability enhancement is characterized by extensive R&D activity that has led to the development of a number of high value technologies and a strong intellectual property portfolio
Several Companies have Begun to Outsource Such Services to Enhance Drug Bioavailability
Outsourcing has emerged as a popular model for improving drug bioavailability; over 150 companies offer a variety of technologies/services based on different approaches
The Current Market is a Mix of Both Well-Established and New Entrants
Entrance of new players has led to a highly fragmented market landscape; however, there are many players that have established a strong foothold over the past several years
Large Sized Companies are Setting Benchmarks by Expanding their Service Portfolios
In fact, stakeholders have steadily added a wide range of capabilities to their service portfolios and are raising existing benchmarks
Collaborative Approach Seems to be the Way Forward
The field has witnessed significant partnering activity; in order to maintain a competitive edge, many players are rapidly expanding offerings through collaborations / acquisitions
Marketed Drugs are Likely to Drive Short-Term Growth for These Technologies
Despite various advancements, the low solubility / permeability concerns related to certain marketed drugs and a large number of NCEs is likely to lead to an increased demand
The Segment is Anticipated to Provide Well-Distributed Opportunity for the Stakeholders
This opportunity is anticipated to be well distributed in terms of drug (BCS) classes, approaches used for bioavailability enhancement and across different geographies
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. Alternatively, you can place an Order by filling this Order Form.
For further information on this domain, check our report here.